Zenas BioPharma (NASDAQ:ZBIO) vs. Pharming Group (NASDAQ:PHAR) Head-To-Head Analysis

Pharming Group (NASDAQ:PHAR) and Zenas BioPharma (NASDAQ:ZBIO) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Pharming Group and Zenas BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pharming Group	2.51%	3.40%	1.90%
Zenas BioPharma	N/A	-122.45%	-58.04%

Earnings and Valuation

This table compares Pharming Group and Zenas BioPharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$376.13 million	2.25	$2.85 million	$0.12	99.58
Zenas BioPharma	$1.00 million	2,153.45	-$377.74 million	($8.99)	-3.68

Pharming Group has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Pharming Group has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500. Comparatively, Zenas BioPharma has a beta of -1.03, meaning that its share price is 203% less volatile than the S&P 500.

Insider & Institutional Ownership

0.0% of Pharming Group shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 22.0% of Zenas BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Pharming Group and Zenas BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	2	0	3	0	2.20
Zenas BioPharma	1	2	6	0	2.56

Pharming Group presently has a consensus target price of $38.67, suggesting a potential upside of 223.57%. Zenas BioPharma has a consensus target price of $45.71, suggesting a potential upside of 38.36%. Given Pharming Group’s higher probable upside, equities analysts clearly believe Pharming Group is more favorable than Zenas BioPharma.

Summary

Pharming Group beats Zenas BioPharma on 10 of the 14 factors compared between the two stocks.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

About Zenas BioPharma

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.